EC
SLRN

EntryPoint Capital’s ACELYRIN SLRN Stock Holding History

EntryPoint Capital’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,830
Closed -$114K – 1267
2024
Q2 		$114K Buy
25,830
+14,797
+134% +$69.4K 0.05% 746
2024
Q1 		$74.5K Sell
11,033
-9,935
-47% -$75.5K 0.07% 569
2023
Q4 		$156K Buy
+20,968
New +$179K 0.15% 172

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

EntryPoint Capital's SLRN Position: Q3 2024 in Review

EntryPoint Capital sold out of ACELYRIN (SLRN) in Q3 2024, closing a stake of 25,830 shares — an estimated $114K sold.

EntryPoint Capital first reported a position in SLRN in Q4 2023 and held it in 3 quarters. The position peaked at $156K in Q4 2023. 122 funds tracked by Wall St. Rank hold SLRN as of Q3 2024.

  • EntryPoint Capital reported no remaining ACELYRIN position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 25,830 ACELYRIN shares in Q3 2024, an estimated $114K.
  • EntryPoint Capital first reported a position in ACELYRIN in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's ACELYRIN position peaked at $156K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.